Source archive for Melanotans
Every claim, receptor measurement, clinical outcome, laboratory assay, and regulatory quotation across this site traces to one of the 54 research papers, reviews, and official agency records cataloged below.
I. Discovery & Receptor Biology
16 sources-
4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity
-
Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics
-
Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin
-
The cloning of a family of genes that encode the melanocortin receptors
-
Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans
-
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
-
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
-
Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans
-
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
-
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
-
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
-
Central role of p53 in the suntan response and pathologic hyperpigmentation
-
Melanocortin Receptors, Melanotropic Peptides and Penile Erection
-
Structure, function and regulation of the melanocortin receptors
-
The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
-
Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin
II. Prescription Medicines & Pivotal Clinical Trials
14 sources-
Afamelanotide for Erythropoietic Protoporphyria
-
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
-
SCENESSE (afamelanotide) implant, for subcutaneous use — Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf
-
Orphan Drug Designations and Approvals: Afamelanotide (SCENESSE)
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208
-
VYLEESI (bremelanotide injection), for subcutaneous use — Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
-
NDA 210557 Approval Letter: Vyleesi (bremelanotide) subcutaneous injection
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
-
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
-
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
-
IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 12/2024)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf
-
An overview of benefits and risks of chronic melanocortin-1 receptor activation
-
IMCIVREE (setmelanotide) injection, for subcutaneous use — Prescribing Information (Revised 03/2026)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf
-
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity
-
Scenesse (afamelanotide) — European Public Assessment Report (EPAR)
-
Imcivree (setmelanotide) — European Public Assessment Report (EPAR)
III. Online Lab Assays & Clinical Case Reports
17 sources-
Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?
-
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
-
Melanotan and the posterior reversible encephalopathy syndrome
-
Melanoma associated with the use of melanotan-II
-
Microbiological contamination in counterfeit and unapproved drugs
-
Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet
-
Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review
-
Are injectable illegal polypeptide drugs safe? Case report demonstrating the presence of haemolytic Bacillus cereus in 2 illegal peptide drugs
-
Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market
-
Falsification of biotechnology drugs: current dangers and/or future disasters?
-
Melanotan-induced priapism: a hard-earned tan
-
Melanotan II: a possible cause of renal infarction: review of the literature and case report
-
Melanotan Tanning Injection: A Rare Cause of Priapism
-
Melanotan II User Experience: A Qualitative Study of Online Discussion Forums
-
Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report
-
Insights into Tanning Biology and Tanning Products
-
Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use
IV. Regulatory Warnings & Compounding
7 sources-
Warning against the tanning product Melanotan
-
FOI 24/274 – Side effects reports of melanotan II products
-
Don’t risk using tanning products containing melanotan
https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan
-
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
-
Consumer advisory: Unapproved peptide products health warning
-
Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526)
-
HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Draft Policy Text and Appendices A & B)